Pirtobrutinib + R-CHOP for Untreated Non-GCB DLBCL
Trial statusNot yet recruiting
Trial phasePhase 2
Trial typeInterventional
Biological sexAll
Age18-80
SponsorChangzhou No.2 People's Hospital
About this trial
To evaluate the efficacy and safety of pirtobrutinib combined with R-CHOP in patients with newly diagnosed non-GCB diffuse large B-cell lymphoma (DLBCL)
Eligibility criteria
Qualifiers
Histopathologically confirmed non-GCB diffuse large B-cell lymphoma (DLBCL) (per the 2016 WHO diagnostic criteria);
Whole-body PET/CT performed within 28 days prior to study enrollment demonstrating at least one measurable lesion (per the 2014 Lugano Criteria);
Age 18-80 years, with estimated survival > 3 months;
No prior anti-lymphoma treatment;
Disqualifiers
Central nervous system involvement;
History of hypersensitivity to the study drug, similar agents, or excipients;
Concurrent other malignancies requiring treatment or intervention;
Major surgical procedure performed within 4 weeks prior to treatment (excluding vascular access catheterization or biopsy);
Trial design
Treatments tested in this trial
- Pirtobrutinib plus R-CHOP
Treatment groups
34 Participants
are divided into 1 treatment groupSponsors and collaborators
Source ClinicalTrials.gov